

**PATIENT INFORMATION**
**PATIENT NAME:** \_\_\_\_\_ **PHONE:** \_\_\_\_\_

**DATE OF BIRTH:** \_\_\_\_\_ **SEX:** ☐ M ☐ F **HEIGHT:** \_\_\_\_\_ **WEIGHT:** \_\_\_\_\_ ☐ LBS ☐ KG

**ALLERGIES:** \_\_\_\_\_ **PREFERRED CLINIC:** \_\_\_\_\_

**REFERRAL STATUS:** ☐ NEW REFERRAL ☐ ORDER CHANGE ☐ ORDER RENEWAL

**DIAGNOSIS & CLINICAL DOCUMENTATION**
☐ E83.31 Familial Hypophosphatemia

☐ E83.39 Other disorders of phosphorus metabolism

☐ E83.8 Other adult osteomalacia

☐ ICD-10 CODE: \_\_\_\_\_ DESCRIPTION: \_\_\_\_\_

**REQUIRED DOCUMENTATION**
☐ Insurance Information

☐ List of Medications

☐ Tried & failed Therapies

☐ Most recent History & Physical

☐ Fasting serum phosphorus

**MEDICATION ORDER**

\*Patient to discontinue oral phosphate & vitamin D analogues 1 week prior to initiation of Crysvita

**For Pediatric Familial Hypophosphatemia**
☐ **PEDS ≥ 10 kg:** Crysvita® (burosumab) 0.8 mg/kg rounded to nearest 10 mg subcutaneously every 2 weeks

\*For peds ≥ 10 kg, minimum dose of 10 mg & maximum dose of 90 mg

**For Adult Familial Hypophosphatemia**
☐ Crysvita® (burosumab) 1 mg/kg rounded to nearest 10 mg subcutaneously every 4 weeks

\*Maximum dose of 90 mg per dose

☐ **OTHER:** \_\_\_\_\_

**LAB ORDERS** \*PRESCRIBER RESPONSIBLE FOR ON-GOING CLINICAL LAB MONITORING

**LAB:** \_\_\_\_\_ **FREQUENCY:** \_\_\_\_\_

☒ **REFILL X 12 MONTHS UNLESS OTHERWISE NOTED HERE:** \_\_\_\_\_

Patient to be observed for 15 minutes following the first injection.

In the event of an adverse reaction occurring in the infusion clinic, utilize the Immersiv Health adverse reaction protocol.

**PRESCRIBER INFORMATION**
**PROVIDER NAME:** \_\_\_\_\_ **NPI #:** \_\_\_\_\_

**EMAIL:** \_\_\_\_\_ **PHONE:** \_\_\_\_\_ **FAX:** \_\_\_\_\_

**ADDRESS (INCLUDE CITY, STATE, ZIP):** \_\_\_\_\_

**SUPERVISING PHYSICIAN:** \_\_\_\_\_ **CONTACT NAME:** \_\_\_\_\_  
(IF APPLICABLE)
**SIGNATURE:** \_\_\_\_\_ **DATE:** \_\_\_\_\_  
(NO STAMPS)

SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN